1996
DOI: 10.1016/s0193-953x(05)70291-4
|View full text |Cite
|
Sign up to set email alerts
|

The Management of Treatment-Resistant Depression in the Medically Ill

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
19
0

Year Published

1998
1998
2014
2014

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 39 publications
(19 citation statements)
references
References 108 publications
0
19
0
Order By: Relevance
“…38,60 These agents appear to be safe and well tolerated in the patients with liver disease. 76,77 Some investigators advocate the use of activating antidepressants, such as fluoxetine, for their potential positive impact on the cognitive and behavioral slowing associated with IFN toxicity. 38 Sertraline is favored for its safety, easy dose titration, tolerability, and favorable pharmacokinetics in patients with advanced liver disease.…”
Section: Management Of Ifn-induced Depressionmentioning
confidence: 99%
See 1 more Smart Citation
“…38,60 These agents appear to be safe and well tolerated in the patients with liver disease. 76,77 Some investigators advocate the use of activating antidepressants, such as fluoxetine, for their potential positive impact on the cognitive and behavioral slowing associated with IFN toxicity. 38 Sertraline is favored for its safety, easy dose titration, tolerability, and favorable pharmacokinetics in patients with advanced liver disease.…”
Section: Management Of Ifn-induced Depressionmentioning
confidence: 99%
“…Although the current data are insufficient for formulating precise guidelines, an approach is suggested in Table 2. 11,38,60,76,79 Controlled trials are needed.…”
Section: Management Of Ifn-induced Depressionmentioning
confidence: 99%
“…Unfortunately, similar to the studies seeking to determine prevalence of depression in diabetes mellitus, treatment studies are confounded by uncontrolled or poorly controlled treatment groups, mixtures of Type I and Type II diabetics, and small numbers of patients enrolled in studies. Recent literature reviews examined the risks and benefits of treating diabetics with classes of antidepressants including tricyclic antidepressants, monoamine oxidase inhibitors, and selective serotonin reuptake inhibitors [49][50][51].…”
Section: Treatmentmentioning
confidence: 99%
“…Monoamine oxidase inhibitors should be avoided if possible because they (1) exaggerate the hypoglycemic response, (2) require stringent dietary modification, further complicating diabetic dietary requirements, and (3) are associated with weight gain [50][51][52][53][54].…”
Section: Treatmentmentioning
confidence: 99%
“…Electroconvulsive seizure (ECS) therapy is one of the most effective antidepressants and the treatment of choice for depressed patients who do not respond to chemical medications (Franco-Bronson, 1996;Stewart and Reid, 2000;Duman, 2002;Nestler et al, 2002). Although electroconvulsive therapy has been used for many years, the molecular mechanisms underlying the efficacy of this treatment remain largely unknown.…”
Section: Introductionmentioning
confidence: 99%